CSO and CEO Dinner

By Life Sciences Pennsylvania (other events)

Wednesday, July 25 2018 6:00 PM 9:00 PM

*This event is reserved for Life Sciences Pennsylvania Core Member Companies. This invitation is only for those who serve in the capacity of chief executive officer, chief science officer, chief medical officer, or head of R&D of a Core member company. If you are not sure of your eligibility, please contact Patrick Hayakawa, Director of Member Relations, [email protected] 

*There is no registration fee. The cost for this event is fully underwritten by our generous sponsors. However, space is limited and you must register for this event if you plan to attend

Join us at St. Davids Golf Club for a relaxed evening to meet new colleagues, reconnect with those familiar, and to hear our guest speaker. 

Where: St. Davids Golf Course
When: Wednesday, July 25, 2018
Time: 6:00 PM - 9:00 PM 

Bruce Levine, Ph.D.
Barbara and Edward Netter Professor in Cancer Gene Therapy University of Pennsylvania Perelman School of Medicine

Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, is the Founding Director of the Clinical Cell and Vaccine Production Facility (CVPF) in the Department of Pathology and Laboratory Medicine and the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania. He received a B.A. (Biology) from Penn and a Ph.D. in Immunology and Infectious Diseases from Johns Hopkins. First-in-human adoptive immunotherapy trials include the first use of a lentiviral vector, the first infusions of gene edited cells, and the first use of lentivirally-modified cells to treat cancer. Dr. Levine has overseen the production, testing and release of 3,000 cellular products administered to >1,200 patients in clinical trials since 1996. T lymphocytes from HIV+ subjects have been rendered resistant to HIV infection and reinfused. T lymphocytes from cancer patients have been redirected with chimeric antigen receptors (CAR's) to hunt and destroy their malignancies. This therapy, developed by the CVPF and licensed by Novartis, recently became the first FDA approved gene therapy (Kymriah). Dr. Levine is co-inventor on 23 issued US patents and co-author of 140 publications with a Google Scholar citation h-index of 71. He is a Co-Founder of Tmunity Therapeutics, a spinout of the University of Pennsylvania. He has been interviewed by the NY Times, Wall Street Journal, Time Magazine, National Geographic, Forbes, BBC, and other international media outlets.


Life Sciences Pennsylvania

Mailing Address

650 East Swedesford Rd, Suite 190 Wayne PA 19087